Browse

Celecoxib Potentiates the Anticancer Effect of Cisplatin on Vulvar Cancer Cells Independently of Cyclooxygenase

DC Field Value Language
dc.contributor.authorKim, Su-Hyeon-
dc.contributor.authorKim, Su-Hyeong-
dc.contributor.authorSong, Yoo-Choel-
dc.contributor.authorSong, Yong-Sang-
dc.date.accessioned2012-06-04T01:47:30Z-
dc.date.available2012-06-04T01:47:30Z-
dc.date.issued2009-
dc.identifier.citationNATURAL COMPOUNDS AND THEIR ROLE IN APOPTOTIC CELL SIGNALING PATHWAYS: : Ann. N.Y. Acad. Sci.; Vol.1171 ; 635-641ko_KR
dc.identifier.issn0077-8923-
dc.identifier.urihttp://hdl.handle.net/10371/76750-
dc.description.abstractCyclooxygenase-2 (COX-2) has been found to be associated with the development and progression of various cancers. Our previous study showed a high expression rate of COX-2 in paraffin-embedded tissue specimens from patients with vulvar cancer. In this study, we evaluated the efficacy of celecoxib, a selective COX-2 inhibitor, as a chemosensitizing agent with cisplatin in vulvar cancer cells A431 and SW962. COX-2 was expressed in both A431 and SW962 vulvar cancer cell lines. COX-1 was expressed in A431 but not in SW962. MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide] assay showed that treatment with 30 mu mol/L celecoxib had no effect on cell growth in A431 cells for 72 h. However, combined treatment with celecoxib and cisplatin induced a significant reduction in cell growth compared to single treatment with cisplatin. Interestingly, single treatment with celecoxib or cisplatin and combined treatment of 10 mu mol/L celecoxib with 10 mu mol/L cisplatin increased COX-2 expression. However, the combination of 30 mu mol/L celecoxib and 30 mu mol/L cisplatin reduced COX-2 expression to the control state. Inhibition of cell growth by celecoxib alone and in combination with cisplatin was independent of the expression level of COX-2 induced by these agents. While treatment with 10 mu mol/L celecoxib or 10 mu mol/L piroxicam significantly suppressed the activity of COX enzymes, neither agent affected the growth of A431 and SW962 cells at this concentration. Taken together, celecoxib could be used as a chemosensitizing agent in vulva cancer cells; the anticancer activity of celecoxib seemed to be independent of COX.ko_KR
dc.language.isoenko_KR
dc.publisherNew York Academy of Sciencesko_KR
dc.subjectcelecoxibko_KR
dc.subjectcisplatinko_KR
dc.subjectvulvar cancerko_KR
dc.subjectcyclooxygenaseko_KR
dc.titleCelecoxib Potentiates the Anticancer Effect of Cisplatin on Vulvar Cancer Cells Independently of Cyclooxygenaseko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor김수현-
dc.contributor.AlternativeAuthor김수형-
dc.contributor.AlternativeAuthor송유철-
dc.contributor.AlternativeAuthor송용상-
dc.identifier.doi10.1111/j.1749-6632.2009.04888.x-
dc.citation.journaltitleNATURAL COMPOUNDS AND THEIR ROLE IN APOPTOTIC CELL SIGNALING PATHWAYS-
dc.description.citedreferenceBijman MNA, 2008, BIOCHEM PHARMACOL, V75, P427, DOI 10.1016/j.bcp.2007.09.005-
dc.description.citedreferenceLee TS, 2007, ANN NY ACAD SCI, V1095, P143, DOI 10.1196/annals.1397.018-
dc.description.citedreferenceLIU B, 2007, CELL BIOL I IN PRESS-
dc.description.citedreferencePyrko P, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-19-
dc.description.citedreferenceShaik MS, 2006, INT J CANCER, V118, P396, DOI 10.1002/ijc.21325-
dc.description.citedreferenceSCHONTHAL AH, 2006, NEUROSURG FOCUS, V20, P1-
dc.description.citedreferenceLewis JD, 2005, GASTROENTEROLOGY, V129, P1865, DOI 10.1053/j.gastro.2005.08.051-
dc.description.citedreferenceHawkey CJ, 2005, GUT, V54, P1509, DOI 10.1136/gut.2005.065003-
dc.description.citedreferenceLin J, 2005, BIOCHEM PHARMACOL, V70, P658, DOI 10.1016/j.bcp.2005.05.028-
dc.description.citedreferenceDandekar DS, 2005, INT J CANCER, V115, P484, DOI 10.1002/ijc.20878-
dc.description.citedreferenceKim SH, 2004, J CANCER RES CLIN, V130, P551, DOI 10.1007/s00432-004-0567-6-
dc.description.citedreferenceHashitani S, 2003, INT J ONCOL, V23, P665-
dc.description.citedreferenceSong XQ, 2002, J NATL CANCER I, V94, P585-
dc.description.citedreferenceWaskewich C, 2002, CANCER RES, V62, P2029-
dc.description.citedreferenceCao Y, 2002, J CELL PHYSIOL, V190, P279, DOI 10.1002/jcp.10068-
dc.description.citedreferenceKOKI AT, 2002, CANC CONTROL S, V9, P28-
dc.description.citedreferenceMONICK MM, 2002, J BIOL CHEM, V277, P23992-
dc.description.citedreferenceZhao SZ, 2001, CLIN THER, V23, P1478-
dc.description.citedreferenceWilliams CS, 1999, ONCOGENE, V18, P7908-
dc.description.citedreferenceWolfe MM, 1999, NEW ENGL J MED, V340, P1888-
dc.description.citedreferenceSingh G, 1999, J RHEUMATOL, V26, P18-
dc.description.citedreferenceVane JR, 1998, ANNU REV PHARMACOL, V38, P97-
dc.description.citedreferenceKALTER E, 1997, INFLAMMATION, V2, P295-
dc.description.tc8-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Obstetrics & Gynecology (산부인과전공)Journal Papers (저널논문_산부인과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse